PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 1987Hypertension155 citationsOpen Access

Ventricular atriopeptin. Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone.

View Full Paper
MDMark L. DayDSDavid A. SchwartzRWRoger C. Wiegand

Key Result

Left ventricular hypertrophy or dexamethasone treatment caused a 2.5- to 3-fold increase in both immunoreactive atriopeptin and its messenger RNA in left ventricular tissue of rats.

Key Points

  • The study aims to explore how left ventricular hypertrophy and dexamethasone treatment affect atriopeptin synthesis.
  • Induced left ventricular hypertrophy through abdominal aortic constriction.
  • Analyzed immunoreactive atriopeptin levels and atriopeptin mRNA in left ventricular and atrial tissues.
  • Used immunohistochemical staining and high-performance liquid chromatography for analysis.
  • Ventricular tissue showed a 2.5- to 3-fold increase in immunoreactive atriopeptin and corresponding mRNA.
  • The combined effects of hypertrophy and dexamethasone increased both atriopeptin levels more than either treatment alone.
  • Immunohistochemical staining confirmed increased atriopeptin synthesis in hypertrophied ventricles.

PICO

P
Population
Left ventricular hypertrophy
I
Intervention / Comparator
Left ventricular hypertrophy (via abdominal aortic constriction) or dexamethasone
O
Primary Outcome
Immunoreactive atriopeptin (AP) and AP messenger RNA (mRNA) levels — 2.5-fold to 3-fold increase

Main Result

Effect estimate: 2.5-fold to 3-fold increase

Abstract

Left ventricular hypertrophy or treatment with dexamethasone caused a 2.5-fold to threefold increase in both immunoreactive atriopeptin (AP) and AP messenger RNA (mRNA), primarily in left ventricular tissue. The combined treatments increased immunoreactive AP and AP mRNA more than either treatment alone. In the animals in which cardiac hypertrophy had been produced by abdominal aortic constriction, there was a decrease in atrial levels of AP and an increase in plasma levels of immunoreactive AP. The increase in left ventricular immunoreactive AP was confirmed by immunohistochemical staining of tissue from hypertrophied and/or dexamethasone-treated rats. The mRNA accumulated in the left ventricle was identical to atrial AP mRNA, as judged by transcriptional start site and by size on Northern blots. Because the mass of ventricular tissue is substantially greater than that of atrial tissue, the induced mRNA levels may represent a total abundance approaching one third of the total AP mRNA in the atria. High performance liquid chromatographic purification of ventricular extracts primarily demonstrated the presence of the high molecular precursor and small amounts of C-terminal peptide AP. Induction of ventricular AP (mRNA and peptide) may represent regression of the tissue to an earlier developmental form. These data provide a unique example of regulation of AP biosynthesis in nonatrial tissue.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Day et al. (1987) studied Left ventricular hypertrophy. Left ventricular hypertrophy (via abdominal aortic constriction) or dexamethasone was evaluated on Immunoreactive atriopeptin (AP) and AP messenger RNA (mRNA) levels (2.5-fold to 3-fold increase). Left ventricular hypertrophy or dexamethasone treatment caused a 2.5- to 3-fold increase in both immunoreactive atriopeptin and its messenger RNA in left ventricular tissue of rats.

synapsesocial.com/papers/6a6387879a2e487662c204d6https://doi.org/10.1161/01.hyp.9.5.485
Ask AI
Helpful
Bookmark
Share
View Full Paper